Firm is initiating its pivotal multicenter, potential, randomized CLARITY trial to construct on scientific proof demonstrating superior surgical outcomes when Nociscan is utilized in surgical decisioning
5 extra Key Opinion Chief (KOL) surgeons anticipated to undertake Nociscan by way of the Alphatec strategic partnership in 1H24
BROOMFIELD, CO, Feb. 05, 2024 (GLOBE NEWSWIRE) — through NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare expertise firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians establish the placement of power low again ache, introduced at the moment that it has accomplished a number of current financing transactions which have considerably decreased debt and elevated accessible money. The Firm believes these financing transactions will help in attaining key milestones that embody initiating the CLARITY trial, onboarding extra KOL surgeons by way of the strategic partnership with Alphatec, and persevering with to extend Nociscan orders.
The financing transactions embody elevating just below $3M of gross proceeds below the beforehand disclosed $10M fairness line and lowering the Firm’s excellent non-convertible debt by $1.5M by way of the conversion of debt into fairness. The Firm believes these current financing transactions have been on phrases extra favorable than these accessible within the public capital markets.
With these proceeds, Aclarion will provoke CLARITY, a potential, multicenter, randomized scientific trial designed to validate the superior surgical outcomes which were proven to outcome when surgical interventions are focused towards intervertebral discs recognized to be painful by Nociscan expertise. CLARITY is anticipated to enroll as much as 300 sufferers throughout roughly 8 websites with Nicholas Theodore, MD, FACS, FAANS, Director of the Neurosurgical Backbone Heart and Professor of Neurosurgery, Orthopedics, and Biomedical Engineering at Johns Hopkins, serving as principal investigator.
Ryan Bond, Chief Technique Officer at Aclarion, mentioned, “We’ve got made nice strides in advancing the scientific knowledge supporting the utilization of Nociscan as a software to enhance surgical decisioning in spine surgical procedure. CLARITY represents the pivotal research we consider will result in nationwide protection selections from each payer of significance, ought to CLARITY outcomes verify these from current peer reviewed printed knowledge. Since Nociscan is a diagnostic, we anticipate to rapidly and cheaply reveal the worth of our expertise compared to the expensive and prolonged scientific trials typical for implantable gadgets.”
The Firm can be advancing by way of the primary phases of the Alphatec strategic partnership. Aclarion and Alphatec management are within the strategy of figuring out 5 KOL surgeons who’re at the moment utilizing Alphatec’s AlphaInformatiX platform and wish to add Nociscan knowledge to their preprocedural planning and surgical decisioning course of. The Firm expects so as to add 5 new KOLs to the Nociscan community within the first half of 2024.
“As we proceed to onboard imaging facilities to fulfill the wants of our core panel of 10 KOLs, we’re excited to work with Alphatec so as to add an extra 5 KOLs to the Aclarion community. As a result of giant variety of surgeons driving Alphatec development, we’ve got the luxurious of constructing our new KOL panel with surgeons who have already got entry to an imaging middle able to performing Nociscans. This may significantly speed up our potential to reap the advantages of surgeon suggestions and speed up not solely Nociscan utilization however development by way of the sequential steps of the strategic partnership,” mentioned Brent Ness, Aclarion CEO.
The Firm will present updates as scientific websites are added to CLARITY and KOLs are onboarded by way of the strategic partnership.
For details about Nociscan please contact Aclarion at email@example.com.
About Aclarion, Inc.
Aclarion is a healthcare expertise firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize scientific therapies. The Firm is first addressing the power low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By way of a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan supplies vital insights into the placement of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For extra data, please go to www.aclarion.com.
This press launch incorporates forward-looking statements throughout the which means of the Personal Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic details, resembling “anticipates,” “believes” and “expects” or related expressions, are forward-looking statements.
This press launch incorporates forward-looking statements, amongst different gadgets, concerning the Firm’s capital elevating plans and wishes for extra capital to proceed fund ongoing operations. Our current plans to boost extra capital could change, and our plans will likely be topic to market situations and different components. All of our forward-looking statements are based mostly on the present plans and expectations of administration and are topic to various uncertainties and dangers that might considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra totally in our filings with the Securities and Trade Fee. Readers are inspired to assessment the part titled “Threat Components” within the Firm’s amended Annual Report on Type 10-Ok, as filed with the Securities and Trade Fee on June 12, 2023, in addition to different disclosures contained in such Annual Report and subsequent filings made with the Securities and Trade Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Kirin M. Smith
PCG Advisory, Inc.